181 related articles for article (PubMed ID: 2903562)
1. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
Vinik AI; Tsai S; Moattari AR; Cheung P
Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
[TBL] [Abstract][Full Text] [Related]
2. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.
Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC
Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
4. The use of somatostatin analog in gastroenteropancreatic tumors other than carcinoid.
Vinik AI; Lloyd R; Cho K
Metabolism; 1990 Sep; 39(9 Suppl 2):156-62. PubMed ID: 2402220
[TBL] [Abstract][Full Text] [Related]
5. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
7. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995).
Ellison EC; Gower WR; Elkhammas E; Woltering EA; Sparks J; O'Dorisio TM; Fabri PJ
Am J Med; 1986 Dec; 81(6B):56-64. PubMed ID: 2879448
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin analogue (SMS 201-995) on molecular species of gastrin in gastrinoma.
Campagnolo D; Gower WR; Fabri PJ; Sparks J; Mekhjian HS; O'Dorisio TM; Ellison EC
Surgery; 1987 Dec; 102(6):982-7. PubMed ID: 2891204
[TBL] [Abstract][Full Text] [Related]
10. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome.
Mozell E; Woltering EA; O'Dorisio TM; Fletcher WS; Sinclair AJ; Hill D
Surg Gynecol Obstet; 1990 Jun; 170(6):476-84. PubMed ID: 2188384
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia.
Geelhoed GW; Bass BL; Mertz SL; Becker KL
Surgery; 1986 Dec; 100(6):962-70. PubMed ID: 2431492
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
13. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
14. Octreotide in control of multiple liver metastases from gastrinoma.
Saijo F; Naito H; Funayama Y; Fukushima K; Shibata C; Hashimoto A; Kitayama T; Nagao M; Matsuno S; Sasaki I
J Gastroenterol; 2003; 38(9):905-8. PubMed ID: 14564638
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma.
Gaztambide S; Vazquez JA
J Endocrinol Invest; 1999 Feb; 22(2):144-6. PubMed ID: 10195383
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
Konturek JW
J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215
[TBL] [Abstract][Full Text] [Related]
17. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report.
Granberg D; Jacobsson H; Oberg K; Gustavsson J; Lehtihet M
Digestion; 2008; 77(2):92-5. PubMed ID: 18376130
[TBL] [Abstract][Full Text] [Related]
18. Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome.
Bauer FE; Hummel M; Merki HS; Schulz E; Oeder R; Marbach P
J Clin Gastroenterol; 1989 Jun; 11(3):282-6. PubMed ID: 2754214
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas.
Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT
Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342
[TBL] [Abstract][Full Text] [Related]
20. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
